Scott D. Grimes Sells 4,098 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLXGet Rating) Director Scott D. Grimes sold 4,098 shares of the stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $50.09, for a total transaction of $205,268.82. Following the sale, the director now directly owns 243,606 shares in the company, valued at $12,202,224.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Cardlytics stock traded down $5.52 during midday trading on Thursday, reaching $40.95. The company had a trading volume of 685,626 shares, compared to its average volume of 382,388. The company has a market capitalization of $1.38 billion, a P/E ratio of -10.29 and a beta of 2.32. Cardlytics, Inc. has a 12-month low of $39.07 and a 12-month high of $145.00. The firm’s fifty day simple moving average is $54.91 and its 200-day simple moving average is $66.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.10 and a quick ratio of 1.10.

Cardlytics (NASDAQ:CDLXGet Rating) last issued its quarterly earnings results on Tuesday, March 1st. The company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.61. The firm had revenue of $90.05 million for the quarter, compared to analyst estimates of $76.59 million. Cardlytics had a negative net margin of 48.13% and a negative return on equity of 12.16%. Cardlytics’s quarterly revenue was up 34.2% compared to the same quarter last year. During the same period last year, the company posted ($0.32) EPS. On average, analysts expect that Cardlytics, Inc. will post -3.64 EPS for the current fiscal year.

CDLX has been the topic of several recent analyst reports. Craig Hallum lowered their target price on shares of Cardlytics from $100.00 to $70.00 in a research note on Wednesday, March 2nd. Wells Fargo & Company initiated coverage on shares of Cardlytics in a research note on Tuesday, April 5th. They set an “overweight” rating and a $72.00 target price on the stock. Needham & Company LLC lowered their target price on shares of Cardlytics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, March 2nd. Finally, Zacks Investment Research raised shares of Cardlytics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 4th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Cardlytics presently has an average rating of “Buy” and an average target price of $83.00.

Hedge funds have recently added to or reduced their stakes in the business. Dark Forest Capital Management LP acquired a new stake in Cardlytics in the 3rd quarter valued at about $39,000. Rockefeller Capital Management L.P. raised its holdings in Cardlytics by 1.5% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 194,229 shares of the company’s stock valued at $16,303,000 after acquiring an additional 2,938 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Cardlytics by 98.3% in the 4th quarter. Russell Investments Group Ltd. now owns 70,803 shares of the company’s stock valued at $4,677,000 after acquiring an additional 35,099 shares during the last quarter. Baillie Gifford & Co. raised its holdings in Cardlytics by 23.1% in the 4th quarter. Baillie Gifford & Co. now owns 917,876 shares of the company’s stock valued at $60,662,000 after acquiring an additional 172,072 shares during the last quarter. Finally, Jump Financial LLC raised its holdings in Cardlytics by 151.8% in the 3rd quarter. Jump Financial LLC now owns 26,436 shares of the company’s stock valued at $2,219,000 after acquiring an additional 15,936 shares during the last quarter. Institutional investors own 96.44% of the company’s stock.

About Cardlytics (Get Rating)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.